VTGN has been in the news 321% more than usual
Feb 18, 2026, 5:35 PM
16.10%
What does VTGN do
VistaGen Therapeutics, a biopharmaceutical company based in South San Francisco, develops treatments for anxiety and depression using intranasal pherines and other therapies targeting central nervous system disorders. The company’s pipeline includes five clinical-stage investigational agents and went public on October 18, 2010.
VTGN has been in the news recently: The Schall Law Firm has filed a class action lawsuit against Vistagen Therapeutics alleging the company made false statements to investors about the PALISADE‑2 Phase 3 trial of fasedienol. Investors who bought Vistagen stock between April 1, 2024 and December 16, 2025 can join the class, and the deadline to seek lead plaintiff status or otherwise act is March 16, 2026.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.